Prostate cancer. Malignant neoplasm of prostate
Conditions
Interventions
Intervention group: In this study, the 225Ac-PSMA-617 radiopharmaceutical is injected intravenously into 10 patients with prostate cancers according to the 68Ga-PSMA-11 PET/CT. Then whole-body scan is
Sponsors
Boushehr University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients must have had progressive metastatic castration-resistant prostate cancer. Patients must have a positive 68Ga-PSMA-11 PET/CT scan. Patients must have recovered or stabilized to = Grade 2 from all clinically significant toxicities related to prior prostate cancer therapy. Patients must have an ECOG performance status of 0 to 2.
Exclusion criteria
Exclusion criteria: Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation or previous PSMA-targeted radioligand therapy. The patient was diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment (Patients with a prior history of malignancy who have been disease-free for more than 3 years are eligible).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numbe of treated prostate cancer patients. Timepoint: 4-6 weeks after last treatment session. Method of measurement: Image-based response using 68Ga-PSMA PET/CT. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Assadi
Boushehr University of Medical Sciences
Outcome results
None listed